Diabetes, Vol 48, Issue 1 117-120, Copyright © 1999 by American Diabetes Association

ARTICLES

Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes

T Umekawa, T Yoshida, N Sakane, A Kogure, M Kondo and H Honjyo
First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.

The recently described variant of the human beta3-adrenergic receptor (AR) gene located mainly in visceral adipocytes is associated with earlier onset of NIDDM, abdominal obesity, insulin resistance, and an increased capacity to gain weight. We investigated whether lipolysis in human omental adipocytes induced by a potent and selective human beta3-AR agonist (L-755,507) was affected by the Trp64Arg mutation of the beta3-adrenoceptor, using 18 omental fat samples obtained during total hysterectomy. The Trp64Arg mutation was determined by polymerase chain reaction-restriction fragment length polymorphism analysis. Arg64 homozygous (n = 4) had a lower median effective concentration (EC50) and lower responsiveness compared with wild-type (n = 8) (EC50: -6.55 +/- 0.21 vs. -7.53 +/- 0.35 log mol/l, P = 0.007; responsiveness: 3.48 +/- 0.32 vs. 5.76 +/- 0.36 micromol x 10(5) cells(-1) x 90 min(-1), P = 0.014, respectively), although there was no difference in lipolysis induced by isoproterenol or CGP12177. Trp64Arg heterozygous (n = 6) also had a significantly lower EC50 and lower responsiveness (EC50: -6.18 +/- 0.09 log mol/l; responsiveness: 4.17 +/- 0.33 micromol x 10(5) cells(-1) x 90 min(-1)). We concluded that the Trp64Arg mutation of the beta3-AR gene is associated with lower lipolytic activities.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Kim, P. A. Pennisi, O. Gavrilova, S. Pack, W. Jou, J. Setser-Portas, J. East-Palmer, Y. Tang, V. C. Manganiello, and D. LeRoith Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1227 - E1236. [Abstract] [Full Text] [PDF]

				M. Kobayashi, K. Takeda, S. Murata, M. Kojima, M. Akahane, Y. Inoue, K. Kitamura, and T. Kawarabayashi Pharmacological Characterization of KUR-1246, a Selective Uterine Relaxant J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 666 - 671. [Abstract] [Full Text]

				W.-C. Hsueh, S. A. Cole, A. R. Shuldiner, B. A. Beamer, J. Blangero, J. E. Hixson, J. W. MacCluer, and B. D. Mitchell Interactions Between Variants in the {beta}3-Adrenergic Receptor and Peroxisome Proliferator-Activated Receptor-{gamma}2 Genes and Obesity Diabetes Care, April 1, 2001; 24(4): 672 - 677. [Abstract] [Full Text]

				I. J. Dionne, A. N. Turner, A. Tchernof, T. I. Pollin, D. Avrithi, D. Gray, A. R. Shuldiner, and E. T. Poehlman Identification of an Interactive Effect of {beta}3- and {alpha}2b-Adrenoceptor Gene Polymorphisms on Fat Mass in Caucasian Women Diabetes, January 1, 2001; 50(1): 91 - 95. [Abstract] [Full Text]

				J. Walston, K. Silver, H. Hilfiker, R. E. Andersen, M. Seibert, B. Beamer, J. Roth, E. Poehlman, and A. R. Shuldiner Insulin Response to Glucose Is Lower in Individuals Homozygous for the Arg 64 Variant of the {beta}-3-Adrenergic Receptor J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4019 - 4022. [Abstract] [Full Text]